Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been given an average recommendation of "Buy" by the nine research firms that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.38.

A number of analysts have recently weighed in on CMPX shares. Wedbush reiterated an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. HC Wainwright upped their target price on Compass Therapeutics from $10.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday. D. Boral Capital reiterated a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Finally, Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CMPX. Tower Research Capital LLC TRC raised its position in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance purchased a new position in Compass Therapeutics in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics during the 4th quarter worth approximately $27,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter worth approximately $30,000. Finally, Mariner LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Price Performance

Compass Therapeutics stock traded down $0.15 during trading hours on Wednesday, hitting $1.46. 1,726,053 shares of the stock traded hands, compared to its average volume of 817,976. The firm's 50 day moving average price is $2.76 and its 200-day moving average price is $2.11. The stock has a market capitalization of $201.89 million, a price-to-earnings ratio of -3.95 and a beta of 1.40. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.